Report: Monoclonal antibodies for dementia lack clear benefits, show risks
By
Kristen Fischer
Jan 23, 2024
Even though amyloid-reducing monoclonal antibodies (MABs) are on the market and some research shows they may treat Alzheimer’s disease and dementia, a new research review found there aren’t clear benefits...